Skip to main content

MINI REVIEW article

Front. Mol. Biosci.
Sec. Molecular Diagnostics and Therapeutics
Volume 11 - 2024 | doi: 10.3389/fmolb.2024.1447315
This article is part of the Research Topic Advances in Diagnostics, Prevention, and Therapeutics by Drug-Delivery System View all 3 articles

Minireview PBMC-engrafted humanized mice models for evaluating immune-related and anticancer drug delivery systems

Provisionally accepted
Yoshie Kametani Yoshie Kametani 1*Ryoji Ito Ryoji Ito 2Yoshiyuki Manabe Yoshiyuki Manabe 3Jerzy K. Kulski Jerzy K. Kulski 4Toshiro Seki Toshiro Seki 5Hitoshi Ishimoto Hitoshi Ishimoto 6Takashi Shiina Takashi Shiina 1
  • 1 Department of Molecular Life Science, Tokai University Shool of Medicine, Isehara, Japan
  • 2 Central Institute for Experimental Medicine and Life Science, Kawasaki, Japan
  • 3 Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Ōsaka, Japan
  • 4 School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia
  • 5 Division of Nephrology, Endocrinology and Metabolism, School of Medicine, Tokai University, Kanazawa, Ishikawa, Japan
  • 6 Department of Obstetrics and Gynecology, School of Medicine, Tokai University, Isehara, Kanagawa, Japan

The final, formatted version of the article will be published soon.

    Immune-related drug delivery systems (DDSs) in humanized mouse models are at the forefront of cancer research and serve as bridges between preclinical studies and clinical applications. These systems offer unique platforms for exploring new therapies and understanding their interactions with human cells and the immune system. Here, we focus on a DDS and a peripheral blood mononuclear cell (PBMC)-engrafted humanized mouse model that we recently developed, and consider some of the key components, challenges, and applications to advance these systems towards better cancer treatment on the basis of a better understanding of the immune response. Our DDS is unique and has a dual function, an anticancer effect and a capacity to fine-tune the immune reaction. The PBL-NOG-hIL-4-Tg mouse system is superior to other available humanized mouse systems for the development of such multifunctional DDSs because it supports the rapid reconstruction of an individual donor’s immunity and avoids the onset of graft-versus-host disease.

    Keywords: humanized mouse, anticancer drug, Immune System, drug delivery system, Hematopoietic Stem Cells, peripheral blood mononuclear cells

    Received: 11 Jun 2024; Accepted: 07 Aug 2024.

    Copyright: © 2024 Kametani, Ito, Manabe, Kulski, Seki, Ishimoto and Shiina. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yoshie Kametani, Department of Molecular Life Science, Tokai University Shool of Medicine, Isehara, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.